Can rubitidine effectively treat diseases

Introduction: Lurbinectedin is a new type of RNA polymerase II inhibitor. Since it was approved by the US FDA in 2020, it has provided new hope for the treatment of patients with metastatic small cell lung cancer (SCLC). As the patents of original drugs gradually expire, their generic drugs have also come out one after another, becoming the focus of patients' attention. This article will detail the therapeutic effects of generic rupitidine in paragraphs and list its contraindications in detail to help patients and medical professionals better understand this drug.

Therapeutic effects of generic drugs of rubitidine

Generic drugs of rubitidine are highly similar to the original drug in terms of chemical structure and mechanism of action, and are designed to replicate the efficacy of the original drug. In clinical trials and practical applications, generic rupitidine drugs have demonstrated significant therapeutic effects.

Overall efficacy: In the treatment of recurrent SCLC patients with disease progression after receiving platinum-based chemotherapy, the overall response rate (ORR) of rupitidine generic drugs can reach more than 30%, and the median duration of response (DOR) and overall survival (OS) are also significantly improved. For platinum-sensitive patients, the efficacy is more significant, and the ORR can be as high as more than 45%.

Combination treatment effect: Studies have shown that generic drugs can further enhance anti-tumor activity when used in combination with chemotherapy drugs such as irinotecan. The overall effective rate of the combined regimen is expected to reach 90%, significantly improving the treatment effect and quality of life of patients.

Effectiveness of individual cases: In practical applications, after receiving generic treatment of lubitidine, the tumors of many SCLC patients significantly shrank or even disappeared, and their condition was effectively controlled. These success stories further demonstrate the effectiveness of generic rupitidine in the treatment of SCLC.

Contraindications of generic rubitidine

Although generic rubitidine has shown good efficacy in the treatment of SCLC, patients still need to pay attention to the following contraindications when using it:

Abnormal liver function: Because rubitidine may cause hepatotoxicity, patients with abnormal liver function should use it with caution. Liver function tests should be performed before use and liver function indicators should be closely monitored during treatment.

Pregnant and lactating women: Rubitidine is embryotoxic and should be avoided by pregnant and lactating women. If you really need to use it, you should take effective contraceptive measures and consult a doctor.

Hematological diseases: Rubitidine may cause hematological diseases such as decreased blood cell count, anemia, and leukopenia. For patients with existing hematological diseases or such risks, they should be used with caution and relevant indicators should be closely monitored during use.

Allergic reaction: If the patient has an allergic reaction to rupitidine or its components (such as urticaria, difficulty breathing, facial swelling, etc.), he should stop taking the drug immediately and seek medical treatment.

Other contraindications: When using generic rubidine drugs, care must be taken to avoid simultaneous use with other drugs that may interact. Patients should use it under the guidance of a professional doctor to ensure drug safety.